Follistatin: Essential role for the N-terminal domain in activin binding and neutralization

被引:59
作者
Sidis, Y
Schneyer, AL
Sluss, PM
Johnson, LN
Keutmann, HT
机构
[1] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Natl Ctr Infertil Res, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
关键词
D O I
10.1074/jbc.M100736200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Follistatin is recognized to be an important regulator of cellular differentiation and secretion through its potent ability to bind and bioneutralize activin with which it is colocalized in many tissue systems. The 288-residue follistatin molecule is comprised of a 63-residue N-terminal segment followed by three repeating 10-cysteine "follistatin domains" also represented in several extracellular matrix proteins. We have used chemical modifications and mutational analyses to define structural requirements for follistatin bioactivity that previously have not been investigated systematically. Mutant follistatins were stably expressed fi om Chinese hamster ovary cell cultures and assayed for activin binding in a solid-phase competition assay. Biological activities were determined by inhibition of activin-mediated transcriptional activity and by suppression of follicle-stimulating hormone secretion by cultured anterior pituitary cells. Deletion of the entire N-terminal domain, disruption of N-terminal disulfides, and deletion of the first two residues each reduced activin binding to <5 % of expressed wild-type follistatin and abolished the ability of the respective mutants to suppress activin-mediated responses in both bioassay systems. Hence, the three follistatin domains inherently lack the ability to bind or neutralize activin. Activin binding was impaired after oxidation of at least one tryptophan, at position 4, in FS-288, Mutation of Trp to Ala or Asp at either positions 4 or 36 eliminated activin binding and bioactivity, Mutation of a third hydrophobic residue, Phe-52, reduced binding to 20% whereas substitutions for the individual Lys and Arg residues in the N-terminal region were tolerated. These results establish that hydrophobic residues within the N-terminal domain constitute essential activin-binding determinants in the follistatin molecule. The correlation among the effects of mutation on activin binding, activin transcriptional responses, and follicle-stimulating hormone secretion substantiates the concept that, at least in the pituitary, the biological activity of follistatin is attributable to its ability to bind and bioneutralize activin.
引用
收藏
页码:17718 / 17726
页数:9
相关论文
共 50 条
[1]   TESTICAN, A MULTIDOMAIN TESTICULAR PROTEOGLYCAN RESEMBLING MODULATORS OF CELL SOCIAL-BEHAVIOR [J].
ALLIEL, PM ;
PERIN, JP ;
JOLLES, P ;
BONNET, FJ .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 214 (01) :347-350
[2]   Agrin isoforms with distinct amino termini: Differential expression, localization, and function [J].
Burgess, RW ;
Skarnes, WC ;
Sanes, JR .
JOURNAL OF CELL BIOLOGY, 2000, 151 (01) :41-52
[3]   Calcium affinity, cooperativity, and domain interactions of extracellular EF-hands present in BM-40 [J].
Busch, E ;
Hohenester, E ;
Timpl, R ;
Paulsson, M ;
Maurer, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (33) :25508-25515
[4]   A HOT-SPOT OF BINDING-ENERGY IN A HORMONE-RECEPTOR INTERFACE [J].
CLACKSON, T ;
WELLS, JA .
SCIENCE, 1995, 267 (5196) :383-386
[5]   Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): Regulation by cell surface follistatin [J].
Delbaere, A ;
Sidis, Y ;
Schneyer, AL .
ENDOCRINOLOGY, 1999, 140 (06) :2463-2470
[6]   Electron microscopic structure of agrin and mapping of its binding site in laminin-1 [J].
Denzer, AJ ;
Schulthess, T ;
Fauser, C ;
Schumacher, B ;
Kammerer, RA ;
Engel, J ;
Ruegg, MA .
EMBO JOURNAL, 1998, 17 (02) :335-343
[7]  
DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328
[8]   Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors [J].
deWinter, JP ;
tenDijke, P ;
deVries, CJM ;
vanAchterberg, TAE ;
Sugino, H ;
deWaele, P ;
Huylebroeck, D ;
Verschueren, K ;
vandenEijndenvanRaaij, AJM .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 116 (01) :105-114
[9]   FOLDING OF PEPTIDE-FRAGMENTS COMPRISING THE COMPLETE SEQUENCE OF PROTEINS - MODELS FOR INITIATION OF PROTEIN FOLDING .1. MYOHEMERYTHRIN [J].
DYSON, HJ ;
MERUTKA, G ;
WALTHO, JP ;
LERNER, RA ;
WRIGHT, PE .
JOURNAL OF MOLECULAR BIOLOGY, 1992, 226 (03) :795-817
[10]  
Eib DW, 1996, J NEUROCHEM, V67, P1047